BIVI

BioVie Inc. (BIVI) | Rumor.io

BioVie

BIVI

Attention (50-day avg)0%

Attention rank (50-day avg)#781

Bullish sentiment (50-day avg)89%

Price to earnings ratio0

Market capitalization13.1M

Earnings per share-3.05

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-22.1M

Social

What share of all stock conversation is about BIVI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% -0.01	0% 0

Sep 15

BioVie Inc.'s Phase 2 trial for bezisterim shows promising results, with a 78% significant improvement over baseline symptoms in severe Long COVID cases.
The trial's topline data will be discussed in a conference call and webcast on September 15, 2026, at 8:30 a.m. Eastern Time.
Bezisterim has been shown to ease fatigue and cognitive symptoms in Long COVID cases, with exploratory gains in high-burden patients.

Generated by AI

Sentiment

Of the messages about BIVI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	50% -38.42	86.61% +1.74
Bearish	—	—	50% +38.42	13.39% -1.74

Bullish· Aug 21

BioVie Inc. (BIVI) has shown significant price stability at $2.00 after a previous rejection, indicating a positive trend.
The stock has demonstrated a multi-day run, with a notable increase in volume, which suggests it has potential for further growth.
The Volume-Weighted Average Price (VWAP) has been fully reclaimed, indicating a strong upward momentum in BIVI's price.

Bearish· Aug 20

The company's stock price has been volatile, with a significant increase followed by a minor move, raising suspicions about potential manipulation or dilution.
There is a concern about naked shorting and possible dilution, with the company's actions being compared to a "trap" for retail traders.
The stock's performance is being compared to a "snake oil" scam, with the company's management being likened to a "greaseball" used car salesperson.

Generated by AI

Topics

Of the messages about BIVI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	58.99%
Technical Analysis	—	—	0%	27.09%
Earnings	—	—	0%	0.25%
Macro	—	—	0%	12.81%
Analysts	—	—	0%	0.86%
Controversies	—	—	0%	0%

Announcements· Mar 5

BioVie Inc. has announced the pricing of a public offering.
BioVie Inc. has completed a public offering.
BioVie Inc. has announced the completion of a public offering.

Technical Analysis· Oct 23

A potential breakout above $4.50 is being watched, with a possibility of reaching $5 or higher.
A bullish pennant is forming on the hourly chart, indicating a possible upward trend.
The stock price is making higher lows while indicators make lower lows, a bullish sign according to the author.

Generated by AI

Community

Of the messages about BIVI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	46.23%	48.38%
Newcomers	—	0%	53.77%	51.62%

Regulars· Aug 20

$BIVI is building momentum in an almost effortless way.
The stock is gaining strength now and may consolidate.
$BIVI appears to be a target for naked shorting.

Newcomers· Aug 21

Newcomers are focusing on the potential for BioVie Inc. ($BIVI) to reach new highs, with some users expressing excitement and optimism about the stock's future performance.
The conversation is centered around the stock's price movements, with users discussing its stabilization and potential for a multi-day run, as well as its premarket performance and the significance of a $300M shelf filing.
Some newcomers are warning others to be cautious about the stock, while others are celebrating their gains, with one user even joking about needing to buy more beer money due to the stock's sudden increase.

Generated by AI

Gold-backed payments, enterprise AI, a Long COVID clinical readout and AI-powered school safety lead a 6:30 p. ET broadcast reaching audiences across the United States, Latin America and MENANEW YORK CITY, NY / ACCESS Newswire / September 26, 2026 / , the financial-media platform for public companies, pre-IPO companies and entrepreneurs, today announced that Show 773 will air tonight at 6:30 p.

3d agoYahoo Finance

New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global

BioVie (Nasdaq:BIVI) CEO Cuong Do Discusses the Company's Recent Long COVID Clinical Results and the Potential of Bezisterim to Address Significant Unmet Patient NeedsNEW YORK CITY, NY / ACCESS Newswire / September 19, 2026 / , one of the world's longest-running sponsored and syndicated business television programs, announces tonight's broadcast featuring executives from BioVie Inc. (Nasdaq:BIVI), Acurx Pharmaceuticals, Inc.

10d agoYahoo! Finance Canada

Alliance Entertainment and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

ORLANDO, FL / ACCESS Newswire / September 18, 2026 / RedChip Companies will air interviews with Alliance Entertainment Holding Corp. (Nasdaq:BIVI) on the RedChip Small Stocks, Big Money™ show, a sponsored television program airing on Bloomberg TV this Saturday, September 19, at 7:00 p.

12d agoYahoo Finance

BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid - Slideshow (NASDAQ:BIVI) 2026-09-17

2026-09-17. The following slide deck was published by BioVie Inc.

12d agoSeeking Alpha

Join BioVie's Exclusive Live Investor Webinar: Inside the ADDRESS-LC Phase 2 Results

BioVie CEO Cuong Do to discuss newly reported Phase 2 data showing bezisterim's potential across key Long COVID symptomsLearn why the ADDRESS-LC findings, together with recent Parkinson's data, could strengthen the case for targeting inflammation and insulin resistance across neurological disordersORLANDO, FL / ACCESS Newswire / September 16, 2026 / RedChip Companies will host an investor webinar on September 23, 2026, at 11:00 a.The exclusive event will feature BioVie President and CEO Cuong Do

14d agoYahoo Finance

What's Going On With BioVie Stock on Tuesday?

14d agoBenzinga

Also Discussed

Investors talking about BIVI also mention

#	Name	Attention
1	Coya Therapeutics, Inc.COYA	0%+0
2	Annovis Bio, Inc.ANVS	0%0
3	Tenon Medical, Inc.TNON	0%new
4	Calidi Biotherapeutics, Inc.CLDI	0%0
5	Anavex Life Sciences CorpAVXL	0.01%+0
6	Aligos Therapeutics, Inc.ALGS	0%new
7	ATHA - Athira Pharma, Inc.	——
8	BTC Digital Ltd.BTCT	0%0
9	Monopar Therapeutics Inc.MNPR	0%0
10	Ainos, Inc.AIMD	0%+0

BioVie Inc.

Healthcare
Biotechnology

BioVie Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and neurodegenerative disorders and advanced liver disease. Its current pipeline centers on investigational drug candidates such as bezisterim, being studied for conditions including Alzheimer’s disease, Parkinson’s disease, and long COVID, and BIV201, which is being developed for complications related to liver cirrhosis and ascites. The company’s work is aimed at addressing chronic, debilitating illnesses through targeted pharmaceutical approaches that seek to reduce inflammation, support neurological function, and manage liver-related fluid retention. BioVie Inc. operates within the biotechnology sector and concentrates on diseases with significant unmet medical needs, making its programs relevant to both neuroscience and hepatology-focused drug development.

Website

Location

680 W. Nye Lane

Carson City, NV, 89703

United States

Social

What share of all stock conversation is about BIVI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% -0.01	0% 0

Sep 15

BioVie Inc.'s Phase 2 trial for bezisterim shows promising results, with a 78% significant improvement over baseline symptoms in severe Long COVID cases.
The trial's topline data will be discussed in a conference call and webcast on September 15, 2026, at 8:30 a.m. Eastern Time.
Bezisterim has been shown to ease fatigue and cognitive symptoms in Long COVID cases, with exploratory gains in high-burden patients.

Generated by AI

Sentiment

Of the messages about BIVI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	50% -38.42	86.61% +1.74
Bearish	—	—	50% +38.42	13.39% -1.74

Bullish· Aug 21

BioVie Inc. (BIVI) has shown significant price stability at $2.00 after a previous rejection, indicating a positive trend.
The stock has demonstrated a multi-day run, with a notable increase in volume, which suggests it has potential for further growth.
The Volume-Weighted Average Price (VWAP) has been fully reclaimed, indicating a strong upward momentum in BIVI's price.

Bearish· Aug 20

The company's stock price has been volatile, with a significant increase followed by a minor move, raising suspicions about potential manipulation or dilution.
There is a concern about naked shorting and possible dilution, with the company's actions being compared to a "trap" for retail traders.
The stock's performance is being compared to a "snake oil" scam, with the company's management being likened to a "greaseball" used car salesperson.

Generated by AI

Topics

Of the messages about BIVI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	58.99%
Technical Analysis	—	—	0%	27.09%
Earnings	—	—	0%	0.25%
Macro	—	—	0%	12.81%
Analysts	—	—	0%	0.86%
Controversies	—	—	0%	0%

Announcements· Mar 5

BioVie Inc. has announced the pricing of a public offering.
BioVie Inc. has completed a public offering.
BioVie Inc. has announced the completion of a public offering.

Technical Analysis· Oct 23

A potential breakout above $4.50 is being watched, with a possibility of reaching $5 or higher.
A bullish pennant is forming on the hourly chart, indicating a possible upward trend.
The stock price is making higher lows while indicators make lower lows, a bullish sign according to the author.

Generated by AI

Community

Of the messages about BIVI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	46.23%	48.38%
Newcomers	—	0%	53.77%	51.62%

Regulars· Aug 20

$BIVI is building momentum in an almost effortless way.
The stock is gaining strength now and may consolidate.
$BIVI appears to be a target for naked shorting.

Newcomers· Aug 21

Newcomers are focusing on the potential for BioVie Inc. ($BIVI) to reach new highs, with some users expressing excitement and optimism about the stock's future performance.
The conversation is centered around the stock's price movements, with users discussing its stabilization and potential for a multi-day run, as well as its premarket performance and the significance of a $300M shelf filing.
Some newcomers are warning others to be cautious about the stock, while others are celebrating their gains, with one user even joking about needing to buy more beer money due to the stock's sudden increase.

Generated by AI

BioVie

Social

Sep 15

Bullish· Aug 21

Bearish· Aug 20

Announcements· Mar 5

Technical Analysis· Oct 23

Regulars· Aug 20

Newcomers· Aug 21

New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global

New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global

Alliance Entertainment and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid - Slideshow (NASDAQ:BIVI) 2026-09-17

Join BioVie's Exclusive Live Investor Webinar: Inside the ADDRESS-LC Phase 2 Results

What's Going On With BioVie Stock on Tuesday?

Also Discussed

BioVie Inc.

Company Information

Location

New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global

New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global

Alliance Entertainment and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid - Slideshow (NASDAQ:BIVI) 2026-09-17

Join BioVie's Exclusive Live Investor Webinar: Inside the ADDRESS-LC Phase 2 Results

What's Going On With BioVie Stock on Tuesday?

Also Discussed

Social

Sep 15

Bullish· Aug 21

Bearish· Aug 20

Announcements· Mar 5

Technical Analysis· Oct 23

Regulars· Aug 20

Newcomers· Aug 21